151 results about "Donepezil" patented technology

Donepezil formulations, including amorphous donepezil or pharmaceutically acceptable salts thereof; sustained-release formulations; and donepezil sprinkle formulations are disclosed.

The present invention relates to an extended release pharmaceutical composition for oral administration comprising donepezil or pharmaceutically acceptable salt thereof and a release-controlling agent. Further, it relates to process for preparation of said compositions.

The invention provides sustained release formulations of basic drugs, stereoisomers of basic drugs, pharmaceutically acceptable salts of basic drugs, and pharmaceutically acceptable salts of stereoisomers of basic drugs. The basic drugs may be anti-dementia drugs, such as cholinesterase inhibitors or memantine. In one embodiment, the cholinesterase inhibitor is donepezil.

The present invention relates to compositions comprising at least one L-type calcium channel blocker, particularly the compound (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate, in combination with at least one cholinesterase inhibitor, particularly donepezil, and uses thereof in methods of treatment.

The invention discloses a long-acting sustained controlled release formulation of donepezil-like composition and a process for preparation. The composition is in the shape of micro-granular. According to the measurement by weight, the invention contains donepezil-like compounds 0.5-5 parts, carrier material of the sustained controlled release formulation 1-500 parts, and further contains other common excipient in pharmacy. The composition is used for anti senile dementia. The frequency of donepezil-like compounds is reduced, and the periodic time of administering medicament is prolonged, the compliance and conformability of the patient are improved, and the bioavailability and the therapeutic index of the donepezil are promoted. Meanwhile the invention discloses a plurality of processes for the preparation of long-acting sustained controlled release formulation of donepezil-like compounds. The process for preparation is flexible. Common processing equipment and commercial scale can be adopted. The production efficiency is high and the quality keeps steady. The invention can be directly or secondly used for making injection or medicament for oral administration.

Provided is a transdermal preparation having low skin irritation as well as a sufficient skin permeability rate of donepezil, which comprises one or more drugs selected from donepezil and pharmaceutically acceptable salts thereof. Also provided are a manufacturing method thereof, and a method for reducing skin irritation of a transdermally absorbable donepezil-containing preparation. An embodiment is a transdermal preparation comprising one or more drugs selected from donepezil and pharmaceutically acceptable salts thereof, and a skin irritation-reducing agent.

Gelled donepezil compositions and methods for making and using the same are provided. The subject compositions include a donepezil active agent in a gelled oral pharmaceutically acceptable vehicle comprising an emulsion of water and oil. Also provided are kits of the subject compositions.

The invention provides a memantine hydrochloride sustained release-donepezil quick release compound capsule and a preparation method thereof. The memantine hydrochloride sustained release-donepezil quick release compound capsule is characterized in that a preparation consists of memantine hydrochloride sustained release pellets and donepezil quick release granules; each sustained release pellet sequentially comprises an empty pellet core, a medicated layer and a sustained release coating layer from inside to outside; and the donepezil quick release granules are prepared from main drugs, other fillers, a disintegrating agent, adhesive and the like. Compared with other dosage forms, the preparation has the features that two drugs are combined so that a complementary synergy effect is achieved, the number of tablets can be reduced, everyday medicine taking load is reduced, and obedience and compliance of a patient can also be improved.

The invention provides methods for treating and/or preventing cognitive impairments, dementia, or neurodegenerative diseases and disorders (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis) in patients by administering therapeutically effective amounts of an AMPA receptor antagonist (e.g., 1,2-dihydropyridine compounds) and therapeutically effective amounts of nootropics (e.g., cholinesterase inhibitors) to patients. The invention also provides combinations, commercial packages, and pharmaceutical compositions comprising therapeutically effective amounts of AMPA receptor antagonists (e.g., 1,2-dihydropyridine compounds) and therapeutically effective amounts nootropics (e.g., cholinesterase inhibitors). The 1,2-dihydropyridine compound may be, for example, 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one. The cholinesterase inhibitor may be, for example, donepezil.

A pharmaceutical combination of memantine and a non-anticholinergic antiemetic agent for the treatment of hypocholinergic disorders in further combination with high doses of donepezil and with solifenacin, and kits comprising said combination. A pharmaceutical combination of memantine and solifenacin for the treatment of hypocholinergic disorders, including Alzheimer type dementia, in further combination with high doses of donepezil, and kits comprising said combination.

Provided is a transdermal delivery system consisting of a backing layer, a drug-containing matrix layer, and a release layer, wherein the drug-containing matrix layer includes (a) donepezil or a pharmaceutically acceptable salt thereof as an active ingredient, (b) a mixture of high molecular weight polyisobutylene having a weight-average molecular weight ranging from 400,000 to 3,000,000 and low molecular weight polyisobutylene having a weight-average molecular weight ranging from 25,000 to 300,000 as an adhesive, and (c) a permeation enhancer in not more than 3% by weight based on the total weight of the drug-containing matrix layer.

The invention discloses a transdermal medicament delivery system containing a donepezil compound, a transdermal preparation and a preparation method. The transdermal medicament delivery system comprises the following components in percentage by weight: 0.1 to 50 percent of donepezil or acid radical salt thereof, 1 to 95 percent of skeleton polymer, 0.1 to 60 percent of transdermal penetration enhancer, 0 to 10 percent of cross linker, 0.5 to 60 percent of humectant, 0.02 to 10 percent of bacteriostatic agent, 0.02 to 30 percent of pH regulator and 0 to 90 percent of solvent. The system is used for treating light, medium and severe senile dementia, can maintain long-time stable medicament delivery of at least 3 days, has better performance, is convenient for medicament delivery, and can reduce the administration frequency and increase the compliance of patients; and meanwhile, the transdermal path avoids first-pass effect on gastrointestinal tracts and liver due to oral administration of medicaments, and the system has higher bioavailability and obvious advantages in medicinal application.

[Object] Discoloration, over time, of a donepezil-containing adhesive preparation is suppressed.

[Solution] At least one species of stabilizer selected from the group consisting of ascorbic acid, a metal salt or an ester thereof, isoascorbic acid or a metal salt thereof, ethylenediamine tetraacetic acid or a metal salt thereof, 2-mercaptobenzimidazole, 3(2)-t-butyl-4-hydroxyanisole, 2,6-di-t-butyl-4-methylphenol, tetrakis[3-(3′,5′-di-t-butyl-4′-hydroxyphenyl)propionic acid]pentaerythritol, (±)-α-tocopherol, (±)-α-tocopherol acetate, rutin, hypophosphorous acid, a metal metabisulfite salt and a metal salt of hydroxymethanesulfinic acid, is blended in a pressure-sensitive adhesive layer containing a pressure-sensitive adhesive and donepezil.

The invention belongs to the medicinal field, in particular to a new application of Gardenia. The technological problem needed to be solved is to provide the new medicinal application of the Gardenia, namely the application in preparing medicines for curing vascular dementia. Proved by experiments, after the inventor adopts a permanent bilateral common carotid artery ligation method and establishes animal models of the vascular dementia and cures the animal models for a month by giving different dosages of geniposide and positive control drug, the inventor carries out behavior and pathological observation for observing the influence of behavior and pathological brain tissue and related biochemical parameters of the geniposide on dementia rats. The inventor finds out that the geniposide with different dosages has functions of improving and recovering cognitive dysfunction of the vascular dementia rats and the rats have dose-dependency, wherein, the geniposide with medium and high dosages has the function of curing the dementia close to donepezil. Therefore, the Gardenia or the geniposide can be adopted for curing the vascular dementia.

Provided herein is a combination therapy useful for the treatment of Alzheimer's disease and Alzheimer's disease related dementia. The combination comprises memantine in an immediate or sustained release form and donepezil in a sustained release form.

The invention relates to a taste-masked donepezil cyclodextrin inclusion compound and an oral instant membrane containing the same, belonging to the technical field of medicine. The oral instant membrane comprises the donepezil cyclodextrin inclusion compound, a film-forming material, a plasticizer, a disintegrating agent and other excipients. Specifically, the oral instant membrane is prepared by including donepezil free alkali in cyclodextrin or a derivative thereof, then dissolving the excipients such as the film-forming material in distilled water, adding an appropriate amount of the donepezil cyclodextrin inclusion compound and preparing a homogeneous solution. The donepezil cyclodextrin inclusion compound provided by the invention completely masks the bad taste of donepezil; the oral instant membrane prepared from the donepezil cyclodextrin inclusion compound has good taste, is rapid in drug release and greatly improves patient compliance; moreover, the taste-masked donepezil cyclodextrin inclusion compound can be applied to other oral dosage forms such as tablets and solutions.

Methods, compositions, and devices for transdermally administering an active agent such as donepezil are provided.

The invention provides a preparation method of donepezil. The method comprises the following steps: using hydride (4) and substituted benzyl ester of substituted sulfuric acid to perform the condensation reaction, and then collecting donepezil (1) from the reaction product. The method of the invention can not generate impurities, the purity of the obtained product is greatly increased, the yield is up to 85%, the reaction time is as short as 2-5 hours, the operation is simple, the stability is good, the equipment investment is small and the method is applicable to industrial production. The reaction formula is shown below.

The present invention provides transdermal absorption preparation having a support, and a drug-containing adhesive layer formed on the support, wherein a drug-containing adhesive layer contains donepezil or a salt thereof, and a higher fatty acid salt.

The present invention provides a transdermal drug delivery system comprising a drug-containing matrix layer comprising: (a) donepezil or a pharmaceutically acceptable salt thereof as an active ingredient; and (b) an acrylate-rubber hybrid as an adhesive.